Search Results

BioTrack Capital and Yonjin Capital join Series A round alongside other investors including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam Capital Upsized and over-subscribed Series A total funding of $44 million secured Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging disease targets

The new additions would bring ACIP membership to 14 total. Several of the proposed members have taken part in anti-vaccine activity or made anti-vaccine statements.

Generous severance packages, getting out of toxic workplaces and finding a better job with better pay are a few reasons respondents to a recent BioSpace survey felt that being laid off was for the best.

In this episode presented by Taconic Biosciences, BioSpace’s head of insights Lori Ellis discusses how preclinical research companies are helping drug developers navigate the current challenging funding environment with Mike Garrett, CEO.

The reprioritization effort will help AC Immune extend its cash runway through the third quarter of 2027.

While the new framework signals continued flexibility at the FDA regarding rare disease approvals, some analysts and advocates question what tangible impacts the new guidelines will have.